Holen Sie sich die Stockscreener-App
1.1723
3.91%
0.0223
Co Diagnostics Inc Aktie (CODX) Neueste Nachrichten
CODX Forecast — Price Target — Prediction for 2027 - TradingView
ARMISTICE CAPITAL, LLC Buys Co-Diagnostics Inc (CODX) -- Shares Look 33% Undervalued on GF Value - GuruFocus
Co-Dx (CODX) Q2 2026 Earnings Call Transcript - The Globe and Mail
CODX Stock Explodes Over 630% In Six Sessions – Retail Traders Bet The Rally Isn’t Over Yet - Stocktwits
Co-diagnostics Company Profile & Introduction - Moomoo
Co-Diagnostics (CODX) Snapshot: Ends Up by 4.37% at $1.31 in the Current Update; Chart View - Vinanet
Co-Diagnostics Inc (CODX) Stock News Today - TradingKey
Co-Diagnostics seeks FDA clearance for new PCR Flu A/B & RSV test, prepping for U.S. launch. - Pluang
Co-Diagnostics joins Utah roundtable on AI and medical devices - Stock Titan
Why Did CODX Stock Nearly Double In Value Today? - Stocktwits
Maxim Group Upgrades Co-Diagnostics to Buy From Hold, $4 Price Target - marketscreener.com
Co-Diagnostics Inc (CODX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Company-diagnostics Stock Price Forecast. Should You Buy CODX? - StockInvest.us
Armistice Capital discloses 9.99% Co-Diagnostics (CODX) holding via Master Fund - Stock Titan
Co-diagnostics | SCHEDULE 13G: Others - Moomoo
Co-Diagnostics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Co-diagnostics(CODX) Stock Options Chain | Quotes & News - Moomoo
CODX|Co-Diagnostics Inc|Price:1.460|Chg%:-0.020 - TradingKey
Co-Diagnostics (CODX) Earnings Call Q2 2026: FDA-Antrag schreitet voran, während Barmittel sinken - TradingKey
Co-Diagnostics (CODX) Q2 2026 Earnings Call: FDA Filing Advances as Cash Falls - TradingKey
Co-Diagnostics Inc (CODX) (Q2 2026) Earnings Call Highlights: FD - GuruFocus
Is Co-Diagnostics Inc (CODX) Undervalued Despite Q2 Earnings Mis - GuruFocus
Co-Diagnostics Q2 Results: Net loss narrows to $6.3 million - scanx.trade
Co-Diagnostics Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
Earnings call transcript: Co-Diagnostics narrows loss in Q2 2026 but revenue stays thin - Investing.com
Co-Diagnostics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Co-Diagnostics (CODX) Stock Falls on Q2 2026 Earnings - Quiver Quantitative
Q2 2026 Co-Diagnostics Inc Earnings Call Transcript - GuruFocus
Co-Diagnostics Q2 2026 Earnings: Losses Narrow as Revenue Stays Near $0.17 Million - TradingKey
Co-Diagnostics (CODX) posts Q2 loss and flags going concern, raises new equity - Stock Titan
Co-Diagnostics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Co-Diagnostics Q2 revenue rises slightly amid international expansion - TradingView
Co-Diagnostics, Inc. (CODX) Latest Stock News & Headlines - Yahoo Finance
Press Release: Co-Diagnostics Reports Second Quarter 2026 Financial Results - 富途牛牛
Co-Diagnostics Inc (CODX) (Q2 2026) Earnings Call Highlights: FDA Submission Milestone and ... By GuruFocus - Investing.com Canada
CODX Q2'26 Earnings: EPS estimate is (3.00) USD - TradingView
Co-Diagnostics Inc expected to post a loss of $3.00 a shareEarnings Preview - TradingView
Co-Diagnostics (NASDAQ: CODX) sees Jane Street disclose 1.7% equity stake - Stock Titan
Co-diagnostics | SCHEDULE 13G/A: Others - Moomoo
Co-Diagnostics Submits Co-Dx PCR Flu A/B & RSV Test for FDA Clearance - respiratory-therapy.com
CODX Stock Price, Quote & Chart - ChartMill
Co-Diagnostics submits FDA 510(k) for respiratory test By Investing.com - Investing.com South Africa
CODX Looks 28.1% Undervalued on GF Value™ Amid Challenging Finan - GuruFocus
Co-Diagnostics submits FDA application for dece... - Pluang
Co-Diagnostics submits FDA 510(k) for respiratory test - Investing.com
Co-Diagnostics Submits FDA 510(k) Premarket Notification for Upper Respiratory Point-of-Care Test - PR Newswire
CODX Q2'26 Earnings: revenue estimate is 132.58K USD - TradingView
Weekly Recap: Co-Diagnostics, Inc. Q2 results date and Bundibugyo test - TradingView
Co-Diagnostics Raises Capital Through Warrant Inducement Ahead of FDA Review - The Clinical Trial Vanguard
Why Is Co-Diagnostics (NASDAQ:CODX) In Focus After Its Latest Molecular Diagnostics Update? - Kalkine Media
Co-Diagnostics holders exercise 1,702,362 warrants at USD 1.57 per share in inducement deal - Bitget
Co-Diagnostics Plans Aug. 13 Webcast on Second-Quarter Results - Stock Titan
Co-Diagnostics Inc (CODX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
EXCLUSIVE: Co-Diagnostics Announces Successful Proof of Concept for Extraction-Free Ebola Test - Yahoo Finance
CODX Looks 3.8% Undervalued on GF Value™ as Market Prices in Cha - GuruFocus
Co-Diagnostics Joint Venture CoSara provides Ebola Test Kits for analytical studies - BioSpectrum Asia
Co-Diagnostics Joint Venture CoSara Provides Ebola Test Kits for Analytical Studies - PR Newswire
Co-Diagnostics, Inc. Announces Amendment to Equity Distribution Agreement with Maxim Group LLC – July 2026 SEC Filing Update – Minichart - Minichart
Co-DiagnosticsAmends Equity Distribution Agreement With Maxim Group For Common Stock SaleSEC Filing - TradingView
Co-Diagnostics Updates ATM With Maxim, Extends Share Standstill to Aug. 14, 2026 - TradingView
Co-Diagnostics Inc (CODX) Cash Flow - TradingKey
Co-Diagnostics Inc (CODX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Co-Diagnostics Inc (CODX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
1.33%
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):